BiologicalDrug
Asfotase alfa clinical trials
Also written ENB-0040 and Strensiq.
- studies test it
- 12
- open now
- 0
- in phase 3
- 1
- first study started
- 2008
How studies write it
Studies that test it under each name
Name
Brand
Studies by the year they started
12 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 9
- Phase 3
- 1
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 1
Alexion Pharmaceuticals, Inc. (11) · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan (1)
Studies
Open first, then newest update. How each study uses asfotase alfa is read from its arms, and is right about nine times in ten.
Testing it · 12
- Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)WithdrawnPhase 2Alexion Pharmaceuticals, Inc.NCT00894075Written as ENB-0040
- Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic DiseaseWithdrawnPhase 4Alexion Pharmaceuticals, Inc.NCT04189315Written as asfotase alfa
- Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)CompletedPhase 2Alexion Pharmaceuticals, Inc.NCT02797821Written as Asfotase alfa
- Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)CompletedPhase 2Alexion Pharmaceuticals, Inc.NCT00952484Written as asfotase alfa
- Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)CompletedPhase 1/2Alexion Pharmaceuticals, Inc.NCT00744042Written as asfotase alfa
- Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)CompletedPhase 1Alexion Pharmaceuticals, Inc.NCT00739505Written as Asfotase Alfa
- Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)CompletedPhase 2/3Alexion Pharmaceuticals, Inc.NCT01176266Written as asfotase alfa
- Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)CompletedPhase 2Alexion Pharmaceuticals, Inc.NCT01203826Written as Asfotase Alfa
- Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)CompletedPhase 2Alexion Pharmaceuticals, Inc.NCT01163149Written as asfotase alfa
- Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)CompletedPhase 2Alexion Pharmaceuticals, Inc.NCT01205152Written as asfotase alfa
- Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in JapanCompletedPhase 4Alexion Pharmaceuticals, Inc.NCT02531867Written as Asfotase Alfa
- Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)CompletedPhase 2Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanNCT02456038Written as Asfotase Alfa (ALXN1215)
Given in every arm · 1 — asfotase alfa is usual care beside what is tested
Codes
What other systems call asfotase alfa · ClinicalTrials.gg INT006006
- MeSH (NLM) C570710asfotase alfaOne source NLM
- UNII (FDA) Z633861EIMASFOTASE ALFAConfirmed FDA, NLM, Wikidata
- RxNorm 1720259Confirmed FDA, Wikidata
- Wikidata Q22075839asfotase alfaConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169788Asfotase AlfaOne source FDA
- DrugBank DB09105One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C570710 | asfotase alfa | One source NLM |
| UNII (FDA) | Z633861EIM | ASFOTASE ALFA | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1720259 | — | Confirmed FDA, Wikidata |
| Wikidata | Q22075839 | asfotase alfa | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169788 | Asfotase Alfa | One source FDA |
| DrugBank | DB09105 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.